Trial · NCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682, Phase 2, Recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reverse Triple Negative Immune Resistant Breast Cancer. Trials, record NCT05076682. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05076682
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reverse Triple Negative Immune Resistant Breast Cancer
- NCT number
- NCT05076682
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz, SHR-A1811, SHR-A2102, SHR-1316, Mecapegfilgrastim, AK131, Theophylline, Mifepristone
- First posted
- 2021-10-13
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | |
| Primary | Immune changes in peripheral blood | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | |
| Secondary | Disease Control Rate (DCR) | Baseline through end of study, assessed up to 6 months | |
| Secondary | Progression Free Survival (PFS) | Randomization to death from any cause, through the end of study,assessed up to 6 months | |
| Secondary | Safety and treatment-related AEs | Randomization to death from any cause, through the end of study,assessed up to 12 months | |
| Secondary | Biomarker analysis1 | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Mast cell function will be measured in pretreatment tissues to predict therapy response. |
| Secondary | Biomarker analysis2 | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Immunohistochemical staining of pre- and post-treatment tissue sections was carried out to evaluate PD-L1 expression, mast cell function, innate lymphoid cell porprotion and activity, and overall inflammatory status |
| Secondary | Biomarker analysis3 | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | The quantity and function of innate lympoid cells will be measured in tissues and/or peripheral blood before and after treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40563015 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05076682
GET https://conductscience.org/api/trials/v1/NCT05076682/registered